Lixte Biotechnology Hldgs Inc Stock Price, News & Analysis

LIXTE Biotechnology Holdings announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial targeting immune therapy unresponsive (MSI Low) metastatic colon cancer. The trial, listed as NCT06012734, will investigate the efficacy of LIXTE's lead compound, LB-100, in combination with Roche's PD-L1 inhibitor, atezolizumab (Tecentriq®). Approximately 85% of colon cancers are MSI Low and non-responsive to immunotherapy. The aim is to enhance immunotherapy efficacy for these patients. The collaboration highlights the scientific potential of LB-100, which has shown promise in pre-clinical data and previous trials. This study is the second recent collaboration with a major pharmaceutical company, following a GSK-supported trial for clear cell ovarian cancer.

LIXTE Biotechnology Holdings has announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) for a new clinical trial targeting MSI Low metastatic colon cancer. The trial, registered as NCT06012734, will test LIXTE's lead compound LB-100 in combination with Roche's PD-L1 inhibitor, atezolizumab. NKI's Dr. Neeltje Steeghs will lead the trial, aiming to improve immunotherapy efficacy for the 85% of colon cancers unresponsive to current treatments. This collaboration follows another recent trial funded by GSK for clear cell ovarian cancer, highlighting the pharmaceutical industry's support for LB-100's potential. This trial could significantly impact colon cancer treatment by making immunotherapy viable for a larger patient group.

LIXTE Biotechnology Holdings announced new pre-clinical data published in EMBO Reports showing that its lead compound, LB-100, can potentially enhance immunotherapy effectiveness in colon cancer. LB-100 has been found to disrupt mRNA splicing in cancer cells, creating neo-antigens that boost immune system recognition. This mechanism could help turn immunologically 'cold' tumors 'hot,' making them more susceptible to immunotherapy. The study, conducted by researchers at the Netherlands Cancer Institute, adds to existing data supporting LB-100's role in sensitizing cancer cells to immune checkpoint blockade. This discovery is expected to expand clinical trial efforts, particularly in lung and ovarian cancer, and could significantly increase the number of colon cancer patients responding to immunotherapy.

LIXTE Biotechnology Holdings has appointed Dr. Jan Schellens as the new Chief Medical Officer, effective August 1, 2024, succeeding Dr. James S. Miser.

Dr. Schellens brings over 25 years of clinical experience in oncology and pharmacology, including leadership roles at prominent institutions like the Netherlands Cancer Institute.

He is expected to significantly contribute to LIXTE's development of LB-100, which aims to enhance chemotherapy and immunotherapy treatments. Dr. Schellens has co-authored over 900 scientific publications and has had significant roles on various medical boards and advisory committees.

LIXTE CEO Bas van der Baan expressed confidence in Dr. Schellens' ability to drive the company's growth and development in cancer therapeutics.

LIXTE Biotechnology provided an update on their recent activities. Key highlights include promising pre-clinical data on their compound LB-100 in a new field of cancer biology called 'activation lethality.' The findings suggest that LB-100 can force cancer cells to lose their cancer-causing properties, potentially opening new treatment strategies alongside ongoing clinical trials in lung, ovarian, and sarcoma cancers. The data was presented by Dr. René Bernards at a major cancer research conference and published in the journal Cancer Discovery.

CEO Bas van der Baan presented at the MedInvest Biotech and Pharma Investor Conference. LIXTE co-sponsored an international workshop at Harvard’s Dana Farber Cancer Institute, discussing innovative cancer therapy approaches. Clinical trials for LB-100 are underway at various prestigious institutions, including the University of Texas MD Anderson Cancer, City of Hope Cancer Center, Sarah Cannon Research Institute, and the Spanish Sarcoma Group. In February 2024, LIXTE signed an exclusive patent license agreement with the NIH. The company's latest financial data is available in their quarterly report filed with the SEC.

LIXTE Biotechnology Holdings, a clinical stage pharmaceutical company, is co-sponsoring an international scientific conference on "Therapeutic Over-Activation in Cancer" at Harvard University's Dana Farber Cancer Institute. The conference will discuss LIXTE's lead clinical compound, LB-100, which has shown promising results in triggering hyper-activation of signals leading to the death of cancer cells. LIXTE's unconventional approach to cancer therapy is based on over-activating oncogenic signaling, presenting a new treatment strategy in cancer therapy.